Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12

Cited by (970)

Items 401–500 of 970

1. The chemical biology of IL-12 production via the non-canonical NFkB pathway
   Peter David Koch, Mikaël J. Pittet, Ralph Weissleder · 2020 · RSC Chemical Biology
2. BET Inhibition Enhances TNF-Mediated Antitumor Immunity
   Lisa C. Wellinger, Simon J. Hogg, Dane M. Newman, Thomas Friess, Daniela Geiss, Jessica Michie, Kelly M. Ramsbottom, Marina Bacac, Tanja Fauti, Daniel Marbach et al. · 2021 · Cancer Immunology Research
3. Systems biology informed neural networks (SBINN) predict response and novel combinations for PD-1 checkpoint blockade
   Michelle Przedborski, Munisha Smalley, Saravanan Thiyagarajan, Aaron J. Goldman, Mohammad Kohandel · 2021 · Communications Biology
4. Capecitabine Can Induce T Cell Apoptosis: A Potential Immunosuppressive Agent With Anti-Cancer Effect
   Sai Zhang, Zhenglu Wang, Shunli Fan, Tao Liu, Sei Yoshida, Shuang Yang, Lei Liu, Wen Hou, Lei Cao, Jianxi Wang et al. · 2021 · Frontiers in Immunology
5. Intratumoral therapies and in-situ vaccination for melanoma
   Laura Ann Huppert, ADIL I. DAUD · 2022 · Human Vaccines & Immunotherapeutics
6. Attenuated Toxoplasma gondii enhances the antitumor efficacy of anti-PD1 antibody by altering the tumor microenvironment in a pancreatic cancer mouse model
   Said Ahmed Bahwal, Jane J. Chen, E Lilin, Taofang Hao, Jiancong Chen, Vern B. Carruthers, Jiaming Lai, Xingwang Zhou · 2022 · Journal of Cancer Research and Clinical Oncology
7. Direct AKT activation in tumor-infiltrating lymphocytes markedly increases interferon-γ (IFN-γ) for the regression of tumors resistant to PD-1 checkpoint blockade
   François Santinon, Fatima Ezzahra Bennani, Meriem Bachais, Alain Pacis, Christopher E. Rudd · 2022 · Scientific Reports
8. Sterile liver injury induces a protective tissue-resident cDC1-ILC1 circuit through cDC1-intrinsic cGAS-STING-dependent IL-12 production
   Andrew D. Hildreth, Eddie T. Padilla, Rana Yakhshi Tafti, Akshara R. Legala, Timothy Edward O’Sullivan · 2023 · Cell Reports
9. Deciphering tumor-infiltrating dendritic cells in the single-cell era
   Qingyu Huang, Fuhao Wang, Hao Di, Xinyu Li, Xiaohui Li, Tianyu Lei, Jinbo Yue, Chao Liu · 2023 · Experimental Hematology and Oncology
10. Cancer vaccines: from an immunology perspective
    Shania Makker, Charlotte Galley, Clare L. Bennett · 2023 · Immunotherapy Advances
11. Tumor β‑catenin expression is associated with immune evasion in non‑small cell lung cancer with high tumor mutation burden
    Satoshi Muto, Yuki Ozaki, Hikaru Yamaguchi, Hayato Mine, Hironori Takagi, Masayuki Watanabe, Takuya Inoue, Takumi Yamaura, Mitsuro Fukuhara, Naoyuki Okabe et al. · 2021 · Oncology Letters
12. Advances in therapeutic cancer vaccines: Harnessing immune adjuvants for enhanced efficacy and future perspectives
    Dekang Ren, Shizheng Xiong, Yujie Ren, Xueni Yang, Xinmiao Zhao, Jiaming Jin, Miaomiao Xu, Tingming Liang, Li Guo, Lixing Weng · 2024 · Computational and Structural Biotechnology Journal
13. The Dendritic Cell Strikes Back
    Christine Moussion, Ira Mellman · 2018 · Immunity
14. In situ Vaccination by Direct Dendritic Cell Inoculation: The Coming of Age of an Old Idea?
    Luciano Castiello, Eleonora Aricò, Giuseppina D'Agostino, Laura Santodonato, Filippo Belardelli · 2019 · Frontiers in Immunology
15. Concomitant inhibition of PPARγ and mTORC1 induces the differentiation of human monocytes into highly immunogenic dendritic cells
    Fernando A. Erra Díaz, Ignacio G. Mazzitelli, Lucía Bleichmar, Claudia Melucci, Asa Thibodeau, Tomás Dalotto‐Moreno, Radu Marcheş, Gabriel A. Rabinovich, Duygu Ucar, Jorge Raul Geffner · 2023 · Cell Reports
16. An optimized IL-12-Fc expands its therapeutic window, achieving strong activity against mouse tumors at tolerable drug doses
    Eva Gutierrez, Mitchell Bigelow, Colin LaCroix, Jeremy Beech, Patrick J. Kirby, Lynn Markowitz, Michael Shifrin, Michael Naill, Alexandra Braun, Steve O'Neil et al. · 2023 · Med
17. Deciphering Cell–Cell Interactions with Integrative Single‐Cell Secretion Profiling
    Linmei Li, Haoran Su, Yahui Ji, Fengjiao Zhu, Jiu Deng, Xue Bai, Huibing Li, Xianming Liu, Yong Luo, Bingcheng Lin et al. · 2023 · Advanced Science
18. Synthetic, Supramolecular, and Self‐Adjuvanting CD8 + T‐Cell Epitope Vaccine Increases the Therapeutic Antitumor Immunity
    Pengxiang Yang, Huijuan Song, Zujian Feng, Changrong Wang, Pingsheng Huang, Chuangnian Zhang, Deling Kong, Weiwei Wang · 2019 · Advanced Therapeutics
19. Immunotherapy in Solid Tumors and Gut Microbiota: The Correlation—A Special Reference to Colorectal Cancer
    Asimina Koulouridi, Ippokratis Messaritakis, Nikolaos Gouvas, John Tsiaoussis, John Souglakos · 2020 · Cancers
20. Advances in the Delivery and Development of Epigenetic Therapeutics for the Treatment of Cancer
    Aparajita Ghosh, Ambati Himaja, Swati Biswas, Onkar P. Kulkarni, Balaram Ghosh · 2023 · Molecular Pharmaceutics
21. Rationally Engineered Bispecific Nanoimmunoblocker Restores Anticancer Immunity via Dual Immune Checkpoint Blockade
    Peixin Guan, Jin Fang, Anqi Zhang, Song Wei Gao, Zhen Liu · 2025 · ACS Nano
22. Programmed cell death in triple-negative breast cancer
    Yaqi Liu, Jin‐Wei He, Jialu Chen, Tianhui Chen, Wei Li, Zhihui Yang, Fancai Zeng · 2025 · Cellular & Molecular Biology Letters
23. Molecular and Immune Biomarkers for Cutaneous Melanoma: Current Status and Future Prospects
    Lorenzo Pilla, Andrea Alberti, Pierluigi di Mauro, Maria Teresa Gemelli, Viola Cogliati, Marina Elena Cazzaniga, Paolo Bidoli, Cristina Maccalli · 2020 · Cancers
24. Cancer vaccines as a targeted immunotherapy approach for breast cancer: an update of clinical evidence
    Maryam Abbaspour, Vajihe Akbari · 2021 · Expert Review of Vaccines
25. Inhibitor of Apoptosis Proteins Antagonist Induces T-cell Proliferation after Cross-Presentation by Dendritic Cells
    Esmée P. Hoefsmit, Paula T. van Royen, Disha Rao, Johanna A. Stunnenberg, Petros Dimitriadis, Cor Lieftink, Ben Morris, Elisa A. Rozeman, Irene L. M. Reijers, Ruben Lacroix et al. · 2023 · Cancer Immunology Research
26. The role of NK cell as central communicators in cancer immunity
    Tobias Bald, Anna‐Marie Pedde, Dillon Corvino, Jan P. Böttcher · 2020 · Advances in immunology
27. Lipid Nanoparticle‐mRNA Engineered Dendritic Cell Based Adoptive Cell Therapy Enhances Cancer Immune Response
    Riddha Das, Xinying Ge, Fan Fei, Sepideh Parvanian, Ralph Weissleder, Christopher Garris · 2024 · Small Methods
28. Unraveling Th subsets: insights into their role in immune checkpoint inhibitor therapy
    Monika E. Ryba-Stanisławowska · 2024 · Cellular Oncology
29. Immunotherapy for gastric cancer: Advances and challenges
    Pei Zhang, Chenyan Zhang, Xiaoying Li, Chen Chang, Cailing Gan, Tinghong Ye, Dan Cao · 2024 · MedComm – Oncology
30. IL-12 drives the expression of the inhibitory receptor NKG2A on human tumor-reactive CD8 T cells
    Olivier Fesneau, Kimberly A. Samson, Wesley K. Rosales, Bretton Jones, Tarsem Lal Moudgil, Bernard A. Fox, Venkatesh Rajamanickam, Thomas M Duhen · 2024 · Nature Communications
31. Overcoming Resistance Mechanisms to Melanoma Immunotherapy
    David X. Zheng, David J. Bozym, Giuseppe Tarantino, Ryan Joseph Sullivan, David Liu, Russell William Jenkins · 2024 · American Journal of Clinical Dermatology
32. Type 2 conventional dendritic cell functional heterogeneity: ontogenically committed or environmentally plastic?
    Beatriz León · 2025 · Trends in Immunology
33. Dendritic Cell Derived‐Extracellular Vesicles Engineered to Express Interleukin‐12 and Anti‐CTLA‐4 on Their Surface for Combinational Cancer Immunotherapy
    Jiangbin Chen, Qi Tan, Zimo Yang, Wenjuan Chen, E. Zhou, Minglei Li, Jingjing Deng, Yali Wu, Jiatong Liu, Juanjuan Xu et al. · 2025 · Journal of Extracellular Vesicles
34. Pharmacological combination of nivolumab with dendritic cell vaccines in cancer immunotherapy: An overview
    João Calmeiro, Mylène A. Carrascal, Adriana Ramos Tavares, Daniel Alexandre Ferreira, Célia M. F. Gomes, Maria Teresa Cruz, Amílcar C. Falcão, Bruno Miguel Neves · 2020 · Pharmacological Research
35. Neoadjuvant Immune Checkpoint Inhibitors for Resectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
    Mei Zhao, Shanwen Chen, Conggui Li, Yingying Du, Ping Li · 2023 · Cancers
36. Mechanism of Qizhen decoction-mediated maturation of DC cells to activate the IL-12/JAK2/STAT4 pathway to sensitise PD-1 inhibitors in the treatment of colorectal cancer
    Xianbin Kong, Qingbo Li, Dong Wang, Miao Wang, Fan Yang, Jingyan Meng · 2023 · Journal of Ethnopharmacology
37. FLT3L-dependent dendritic cells control tumor immunity by modulating Treg and NK cell homeostasis
    Paul Régnier, Mathias Vétillard, Adèle Bansard, Eméranne Pierre, Xinyue Li, Nicolas Cagnard, Emmanuel L. Gautier, Pierre Guermonprez, Bénédicte Manoury, Katrina Podsypanina et al. · 2023 · Cell Reports Medicine
38. p53 suppresses MHC class II presentation by intestinal epithelium to protect against radiation-induced gastrointestinal syndrome
    Jianming Wang, Chun‐Yuan Chang, Xue Feng Yang, Fan Zhou, Juan Liu, Jill Bargonetti, Lanjing Zhang, Ping Xie, Zhaohui Feng, Wenwei Hu · 2024 · Nature Communications
39. Type III interferon inhibits bladder cancer progression by reprogramming macrophage-mediated phagocytosis and orchestrating effective immune responses
    Bo Wang, Bingkun Zhou, Junyu Chen, Xi Hong Sun, Wenjuan Yang, Tenghao Yang, Hao Yu, Peng Chen, Ke Chen, Xiaodong Huang et al. · 2024 · Journal for ImmunoTherapy of Cancer
40. When DNA damage responses meet tumor immunity: From mechanism to therapeutic opportunity
    Dong Pan, Qi Wang, Aihua Shen, Zhihao Qi, Chunfu Zheng, Burong Hu · 2024 · International Journal of Cancer
41. Myeloid Cell-Targeted Nanocarriers Efficiently Inhibit Cellular Inhibitor of Apoptosis for Cancer Immunotherapy
    Peter David Koch, Christopher B. Rodell, Rainer H. Köhler, Mikaël J. Pittet, Ralph Weissleder · 2020 · Cell chemical biology
42. Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation
    Brendan Paul Hodkinson, Michael Schäffer, Joshua Brody, Wojciech J. Jurczak, Cecilia del Carmen Carpio, Dina Ben‐Yehuda, Irit Mazza Avivi, Ann Forslund, Muhıt Özcan, John David Alvarez et al. · 2020 · Translational Oncology
43. Dendritic cells type 1 control the formation, maintenance, and function of tertiary lymphoid structures in cancer
    Raphaël Mattiuz, Jesse Boumelha, Pauline Hamon, Jessica Le Bérichel, Abishek Balachandra Vaidya, Brian Y. Soong, László Halász, Emir Radkevich, Hye Mi Kim, Matthew D. Park et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
44. Immune Checkpoint Inhibitor-Associated Cutaneous Adverse Events: Mechanisms of Occurrence
    Abdulaziz M. Eshaq, Thomas Wayne Flanagan, Abdulqader Ali Ba Abbad, Zain Alabden A. Makarem, Mohammed S. Bokir, Ahmed Khaled Alasheq, Sara A. Al Asheikh, Abdullah Mohammed Almashhor, Faroq Binyamani, Waleed A. Al-Amoudi et al. · 2024 · International Journal of Molecular Sciences
45. Positioning and reversible suppression of CCR7+ dendritic cells in perivascular tumor niches shape cancer immunity
    Béatrice Zitti, Florent Duval, Pratyaksha Wirapati, Mehdi Hicham, Yuxuan Xie, Juhyun Oh, Jan Hoelzl, Philippa Meiser, Marco Varrone, Hannah M. Peterson et al. · 2025 · Immunity
46. Identification of Potential Biomarkers for Anti-PD-1 Therapy in Melanoma by Weighted Correlation Network Analysis
    Xuanyi Wang, Zixuan Chai, Yinghong Li, Fei Long, Youjin Hao, Guizhi Pan, Mingwei Liu, Bo Li · 2020 · Genes
47. IL-33 Induces Sema4A Expression in Dendritic Cells and Exerts Antitumor Immunity
    Yasuhiko Suga, Izumi Nagatomo, Yuhei Kinehara, Shohei Koyama, Daisuke Okuzaki, Akio Osa, Yujiro Naito, Hyota Takamatsu, Masayuki Nishide, Satoshi Nojima et al. · 2021 · The Journal of Immunology
48. Amplification of the CXCR3/CXCL9 axis via intratumoral electroporation of plasmid CXCL9 synergizes with plasmid IL-12 therapy to elicit robust anti-tumor immunity
    Jack Y. Lee, Bianca Nguyen, Anandaroop Mukhopadhyay, Mia Han, Jun Zhang, Ravindra Gujar, Jon V. Salazar, Reneta Hermiz, Lauren Svenson, Erica Browning et al. · 2022 · Molecular Therapy — Oncolytics
49. Discovery of potent immune-modulating molecule taccaoside A against cancers from structures-active relationships of natural steroidal saponins
    Zhi Dai, Pei-Feng Zhu, Hui Liu, Xuanchen Li, Yan-Yan Zhu, Yangyang Liu, Xiaolong Shi, Wei-Di Chen, Yaping Liu, Yun‐Li Zhao et al. · 2022 · Phytomedicine
50. Neoadjuvant Immunotherapy for Hepatocellular Carcinoma
    Thomas Urban Marron, M. Schwartz, Virginia Corbett, Miriam Mérad · 2022 · Journal of Hepatocellular Carcinoma
51. Inhibition of HCK in myeloid cells restricts pancreatic tumor growth and metastasis
    Ashleigh R. Poh, Megan O’Brien, David Chisanga, Hong He, David Baloyan, Jasmin Traichel, Christine Dijkstra, Michaël Chopin, Stephen L. Nutt, Lachlan W. Whitehead et al. · 2022 · Cell Reports
52. The role of interferons in ovarian cancer progression: Hinderer or promoter?
    Taiqing Liu, Yinqi Li, Xiaoyu Wang, Xiaodong Yang, Yunhai Fu, Yeteng Zheng, Hanlin Gong, Zhiyao He · 2022 · Frontiers in Immunology
53. Triple-serotype chimeric oncolytic adenovirus exerts multiple synergistic mechanisms against solid tumors
    Yinghan Su, Jiang Li, Weidan Ji, Gang Wang, Lin Fang, Qin Zhang, Lin Ang, Min Zhao, Sen Yuan, Lei Chen et al. · 2022 · Journal for ImmunoTherapy of Cancer
54. Immune interactions in pembrolizumab (PD-1 inhibitor) cancer therapy and cardiovascular complications
    Abha Banerjee, Chandrakala Aluganti Narasimhulu, Dinender Kumar Singla · 2023 · American Journal of Physiology-Heart and Circulatory Physiology
55. Engineering cytokines for tumor-targeting and selective T cell activation
    Kun Peng, Yang‐Xin Fu, Yong Liang · 2025 · Trends in Molecular Medicine
56. Fascin Inhibitors Decrease Cell Migration and Adhesion While Increase Overall Survival of Mice Bearing Bladder Cancers
    Zhankui Zhao, Yufeng Wang, J. Jillian Zhang, Xin‐Yun Huang · 2021 · Cancers
57. Rapid Serial Immunoprofiling of the Tumor Immune Microenvironment by Fine Needle Sampling
    Juhyun Oh, Jonathan Carlson, Christian Landeros, Hakho Lee, Scott W. Ferguson, William C. Faquin, John Ross Clark, Mikaël J. Pittet, Sara Isabel Pai, Ralph Weissleder · 2021 · Clinical Cancer Research
58. Targeting TCTP sensitizes tumor to T cell-mediated therapy by reversing immune-refractory phenotypes
    Hyo-Jung Lee, Kwon‐Ho Song, Se Jin Oh, Suyeon Kim, Eunho Cho, Jungwon Kim, Yun Gyu Park, Kyung‐Mi Lee, Cassian Yee, Seung-Hwa Song et al. · 2022 · Nature Communications
59. Combinations of Toll-like receptor 8 agonist TL8-506 activate human tumor-derived dendritic cells
    He Mi, Bhavesh Soni, Petra Catalina Schwalie, Tamara Hüsser, Caroline Waltzinger, Duvini De Silva, Ylva Prinz, Laura Krümpelmann, Samuele Calabrό, Ines Grazina de Matos et al. · 2022 · Journal for ImmunoTherapy of Cancer
60. Excessive immunosuppression by regulatory T cells antagonizes T cell response to schistosome infection in PD-1-deficient mice
    Liaoxun Lu, Tianhan Li, Xinyu Feng, Zhilong Liu, Yang Liu, Tianzhu Chao, Yanrong Gu, Rong Huang, Fanghui Zhang, Le D. He et al. · 2022 · PLoS Pathogens
61. A therapeutic DC vaccine with maintained immunological activity exhibits robust anti-tumor efficacy
    Yichao Lu, Yingying Shi, Yu Liu, Zhenyu Luo, Junlei Zhang, Mengshi Jiang, Xiang Li, Xu Liu, Xuemeng Guo, Bing Qin et al. · 2022 · Journal of Controlled Release
62. An affinity threshold for maximum efficacy in anti-PD-1 immunotherapy
    Sarah C. Cowles, Allison M. Sheen, Luciano Santollani, Emi A. Lutz, Brianna M. Lax, Joseph R. Palmeri, Gordon James Freeman, Karl Dane Wittrup · 2022 · mAbs
63. Reviewing the significance of dendritic cell vaccines in interrupting breast cancer development
    Namrata Gautam, Ganesan Ramamoorthi, Nicholas Champion, Hyo Sook Han, Brian J. Czerniecki · 2023 · Molecular Aspects of Medicine
64. Targeting STAT3 in tumor-associated antigen-presenting cells as a strategy for kidney and bladder cancer immunotherapy
    Marice B. Alcantara, Wilson S. Tang, Dongfang Wang, Damian Kaniowski, Elaine Y. Kang, Nazlı Dizman, Alex Chehrazi‐Raffle, Luis Alfredo Meza, Zeynep Büşra Zengin, Jeremy Hall et al. · 2024 · Frontiers in Immunology
65. The war between the immune system and the tumor - using immune biomarkers as tracers
    Kai Yang, Rongrong Lu, Jie Mei, Kai Cao, Tianyu Zeng, Yijia Hua, Xiang Huang, Wei Li, Yongmei Yin · 2024 · Biomarker Research
66. The C5a/C5aR1 Axis Promotes Migration of Tolerogenic Dendritic Cells to Lymph Nodes, Impairing the Anticancer Immune Response
    Yaiza Senent, Ana Remírez, David Repáraz, Diana Llópiz, Daiana Pamela Celias, Cristina Sainz, Rodrigo Entrialgo‐Cadierno, Lucía Suárez, Ana Rouzaut, Diego Alignani et al. · 2024 · Cancer Immunology Research
67. The role of dendritic cells for therapy of B-cell lymphoma with immune checkpoint inhibitors
    Anne Scheuerpflug, Fatima Ahmetlić, Vera Bauer, Tanja Riedel, Martin Röcken, Ralph Mocikat · 2020 · Cancer Immunology Immunotherapy
68. Targeted SPP1 Inhibition of Tumor‐Associated Myeloid Cells Effectively Decreases Tumor Sizes
    Benan Kartal, Christopher Garris, Hyung Shik Kim, Rainer H. Köhler, Jasmine E. Carrothers, Elias A. Halabi, Yoshiko Iwamoto, Anne‐Gaëlle Goubet, Yuxuan Xie, Pratyaksha Wirapati et al. · 2024 · Advanced Science
69. Empowering hypoxia to convert cold tumors into hot tumors for breast cancer immunotherapy
    Lu Liu, Danping Wu, Zhiwen Qian, Jiang Ying, Yilan You, YiDa Wang, Feng Zhang, Xin Ning, Jie Mei, Jabed Iqbal et al. · 2025 · Cell Death Discovery
70. Overcoming Resistance to Immunotherapy in Advanced Cutaneous Squamous Cell Carcinoma
    Natalia García‐Sancha, Roberto Corchado‐Cobos, Lorena Bellido-Hernández, Concepción Román‐Curto, Esther Cardeñoso Álvarez, Jesús Pérez‐Losada, Alberto Órfão, Javier Cañueto · 2021 · Cancers
71. Chrysin enhances antitumour immunity response through the IL‐12‐STAT4 signal pathway in the B16F10 melanoma mouse model
    Ran Lu, Shuang Wang, Shasha Jiang, Chenglin Li, Yashuo Wang, Ling Li, Yunyang Wang, Guixin Ma, Hongye Qiao, Zhe Leng et al. · 2022 · Scandinavian Journal of Immunology
72. Norcantharidin liposome emulsion hybrid delivery system enhances PD-1/PD-L1 immunotherapy by agonizing the non-canonical NF-κB pathway
    Zixu Liu, Linxuan Zhao, Hao Liu, Nan Dong, Ning Zhou, Yu Xin Zhang, Tian Yin, Haibing He, Jingxin Gou, Xing Tang et al. · 2022 · International Journal of Pharmaceutics
73. MHC Class II is Induced by IFNγ and Follows Three Distinct Patterns of Expression in Colorectal Cancer Organoids
    Oliver J. Pickles, Kasun Wanigasooriya, Anetta Ptasinska, Akshay Jatin Patel, Helen L. Robbins, Claire Bryer, Celina Whalley, Louise J. Tee, Neeraj Lal, Claudia Maria Assunta Pinna et al. · 2023 · Cancer Research Communications
74. Perspectives on Psoriasiform Adverse Events from Immune Checkpoint Inhibitors: Lessons Learned from Our Practice
    Liliana Gabriela Popa, Călin Giurcăneanu, Mariana Georgiana Portelli, Mara Mădălina Mihai, Cristina Beiu, Olguța Anca Orzan, Ana Ion, T. Anghel · 2024 · Medicina
75. Beyond CAR-T: The rise of CAR-NK cell therapy in asthma immunotherapy
    Mohadeseh Mohammad Taheri, Fatemeh Javan, Mohadeseh Poudineh, Seyed Shamseddin Athari · 2024 · Journal of Translational Medicine
76. Unleashing Tumour-Dendritic Cells to Fight Cancer by Tackling Their Three A’s: Abundance, Activation and Antigen-Delivery
    Aleksandar Murgaski, Pauline M. R. Bardet, Sana M. Arnouk, Emile J. Clappaert, Damya Laoui · 2019 · Cancers
77. Role of inflammasome activation in tumor immunity triggered by immune checkpoint blockers
    Mercedes Segovia, Sofía Russo, María Romina Girotti, Gabriel A. Rabinovich, Marcelo Hill · 2020 · Clinical & Experimental Immunology
78. Immunogenic chemotherapy effectively inhibits KRAS-Driven lung cancer
    Dong Wang, Jingjing Cong, Binqing Fu, Xiaohu Zheng, Rui Sun, Zhigang Tian, Haiming Wei · 2020 · Cancer Letters
79. Next Generation Imaging Techniques to Define Immune Topographies in Solid Tumors
    Violena Pietrobon, Alessandra Cesano, Francesco Maria Marincola, Jakob Nikolas Kather · 2021 · Frontiers in Immunology
80. Type I and II interferons toward ideal vaccine and immunotherapy
    Burcu Temizoz, Ken J. Ishii · 2021 · Expert Review of Vaccines
81. CD24, not CD47, negatively impacts upon response to PD‐1/L1 inhibitors in non–small‐cell lung cancer with PD‐L1 tumor proportion score < 50
    Yuichi Ozawa, Yuhei Harutani, Jun Oyanagi, Hiroaki Akamatsu, Eriko Murakami, Ryota Shibaki, Atsushi Hayata, Takeya Sugimoto, Masanori Tanaka, Toshiaki Takakura et al. · 2020 · Cancer Science
82. The Role of Myeloid Cells in Hepatotoxicity Related to Cancer Immunotherapy
    Cathrin L. C. Gudd, Lucia A. Possamai · 2022 · Cancers
83. In vitro evidence of oncofetal antigen and TLR-9 agonist co-delivery by alginate nanovaccines for liver cancer immunotherapy
    Mengyue Pei, Huiyang Li, Yingwei Zhu, Jian Lü, Chuangnian Zhang · 2022 · Biomaterials Science
84. From simplicity to complexity in current melanoma models
    Elisabetta Michielon, Tanja D. de Gruijl, Susan Gibbs · 2022 · Experimental Dermatology
85. Enhancing Efficacy of TCR-engineered CD4+ T Cells Via Coexpression of CD8α
    Victoria E. Anderson, Sara Brilha, Anika M. Weber, Annette Pachnio, Guy E. Wiedermann, Sumaya Dauleh, Tina Ahmed, George R. Pope, Laura L. Quinn, Roslin Y. Docta et al. · 2023 · Journal of Immunotherapy
86. The role of dendritic cells in radiation-induced immune responses
    Aanchal Preet Kaur, Alejandro F. Alice, Marka R. Crittenden, Michael J. Gough · 2023 · International review of cytology
87. Combinatorial Immunotherapy with Agonistic CD40 Activates Dendritic Cells to Express IL12 and Overcomes PD-1 Resistance
    Irina Krykbaeva, Kate Bridges, William Damsky, Gabriela A. Pizzurro, Amanda F. Alexander, Meaghan K. McGeary, Koonam Park, Viswanathan Muthusamy, Jim E. Eyles, Nadia Luheshi et al. · 2023 · Cancer Immunology Research
88. Human NLRC4 expression promotes cancer survival and associates with type I interferon signaling and immune infiltration
    Charlotte Domblides, Steven Crampton, Hong Liu, Juliet M. Bartleson, Annie Nguyen, Claudia Champagne, Emily Landy, Lindsey Spiker, Chris Proffitt, Sunil Bhattarai et al. · 2024 · Journal of Clinical Investigation
89. Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee
    Anne Monette, Sarah Warren, J. Carl Barrett, Charlie Garnett‐Benson, Kurt Alex Schalper, Janis Marie Taube, Brian Gregory Topp, Alexandra Snyder · 2024 · Journal for ImmunoTherapy of Cancer
90. Exosomes as a Therapeutic Strategy in Cancer: Potential Roles as Drug Carriers and Immune Modulators
    Azam Abedi, Mehrdad Moosazadeh Moghaddam, Reza Kachuei, Abbas Ali Imani Fooladi · 2024 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
91. Novel intravesical bacterial immunotherapy induces rejection of BCG-unresponsive established bladder tumors
    Eduardo Moreo, Santiago Uranga, Ana Picó, Ana Belén Gómez, Denise Nardelli‐Haefliger, Carlos del Fresno, Ingrid Murillo, Eugenia Puentes, Esteban Rodríguez, Mar Valés‐Gómez et al. · 2022 · Journal for ImmunoTherapy of Cancer
92. Candidate approaches for predicting vitiligo recurrence: an effective model and biomarkers
    Binhao Liu, Jiacheng Shen, Jiayu Li, Bowen Tian, Bin Zhou, Jiachen Gui, Zhimin Li, Yue Zhang, Wenzhi Hu, Qiang Li · 2025 · Frontiers in Immunology
93. Non-depleting reformation of immunosuppressive myeloid cells to broaden the application of anti-PD therapy
    Si‐Yuan Peng, Lei Chen, Ronghui Deng, Hao Li, Xinhua Liu, Diwei Zheng, Cong‐Cong Wu, Chuan‐Jun Liu, Zhi‐Jun Sun, Xian‐Zheng Zhang · 2021 · Nanoscale
94. A novel anti-CD47-targeted blockade promotes immune activation in human soft tissue sarcoma but does not potentiate anti-PD-1 blockade
    Andrej Ozaniak, Jitka Smetanová, Robin Bartolini, Michal Rataj, Linda Čapková, Jaromír Háček, Martina Fialová, Lenka Krupickova, Ilja Střı́ž, Robert Lischke et al. · 2022 · Journal of Cancer Research and Clinical Oncology
95. IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancer
    Jeffrey L. Wong, Patrick Smith, Juan Carlos Angulo-Lozano, Daniel L Ranti, Bernard H. Bochner, John P. Sfakianos, Amir Horowitz, Jeffrey V. Ravetch, David A. Knorr · 2023 · Proceedings of the National Academy of Sciences
96. Highly Active Myeloid Therapy for Cancer
    Ina R. Fredrich, Elias A. Halabi, Rainer H. Köhler, Xinying Ge, Christopher Garris, Ralph Weissleder · 2023 · ACS Nano
97. BCG as an Innovative Option for HCC Treatment: Repurposing and Mechanistic Insights
    Farzam Vaziri, Tahereh Setayesh, Ying Chuan Hu, Resmi K. Ravindran, Dongguang Wei, Yu‐Jui Yvonne Wan · 2024 · Advanced Science
98. The impact of Foxp3 + regulatory T‐cells on CD8 + T‐cell dysfunction in tumour microenvironments and responses to immune checkpoint inhibitors
    Mikhaël Attias, Ciriaco A. Piccirillo · 2024 · British Journal of Pharmacology
99. Resiquimod-loaded cationic liposomes cure mice with peritoneal carcinomatosis and induce specific anti-tumor immunity
    Po‐Han Chao, Vanessa Chan, Jiamin Wu, Lucas J. Andrew, Shyh‐Dar Li · 2024 · Journal of Controlled Release
100. Updating Neuroimmune Targets in Central Nervous System Dysfunction
     L.A. Valente, Lauren R. Begg, Anthony J. Filiano · 2019 · Trends in Pharmacological Sciences